MyFinsight
Home
Blog
About
Proceeds from sale of
property and equipment
$61K
Effect of exchange
rates on cash, cash...
$471K
(-94.41%↓ Y/Y)
Net cash provided
by/(used) in investing...
$61K
(264.86%↑ Y/Y)
Net decrease in
cash, cash...
-$7,559K
(69.29%↑ Y/Y)
Canceled cashflow
$532K
Prepaid expenses and
other current assets
-$1,915K
(-460.64%↓ Y/Y)
Depreciation and
amortization
$820K
(-79.68%↓ Y/Y)
Unrealized foreign
exchange (gain)/loss
-$441K
(90.94%↑ Y/Y)
Share based
compensation
$433K
(131.55%↑ Y/Y)
Non-cash lease expenses
$205K
(-87.64%↓ Y/Y)
Accrued expenses and
other current...
$104K
(103.76%↑ Y/Y)
Change in contingent
consideration
$89K
(126.25%↑ Y/Y)
Non-cash interest
expense
$14K
(-44.00%↓ Y/Y)
Net cash used in
operating activities
-$8,091K
(75.49%↑ Y/Y)
Canceled cashflow
$4,021K
Net loss
-$10,599K
(74.01%↑ Y/Y)
Operating lease
liabilities
-$958K
(1.54%↑ Y/Y)
Accounts payable
-$451K
(44.53%↑ Y/Y)
Research and development
incentives receivable
$44K
(101.42%↑ Y/Y)
Profit on sale of
property and equipment
$32K
(-88.61%↓ Y/Y)
Deferred tax benefit
-$23K
(51.06%↑ Y/Y)
Deferred income
-$5K
(98.54%↑ Y/Y)
Back
Back
Cash Flow
Barinthus Biotherapeutics plc. (BRNS)
Barinthus Biotherapeutics plc. (BRNS)
source: myfinsight.com